Brain

Groundbreaking Study on Omega-3 DHA Enriched Foods to Enhance Public Health in Saudi ArabiaGroundbreaking Study on Omega-3 DHA Enriched Foods to Enhance Public Health in Saudi Arabia

Groundbreaking Study on Omega-3 DHA Enriched Foods to Enhance Public Health in Saudi Arabia

RIYADH, Saudi Arabia, April 17, 2025 /PRNewswire/ -- In a significant advancement for public health, the results of the landmark…

3 weeks ago
NMN Supplement: Best NMN Supplements To Boost NAD From Genuine Purity Liposomal NMNNMN Supplement: Best NMN Supplements To Boost NAD From Genuine Purity Liposomal NMN

NMN Supplement: Best NMN Supplements To Boost NAD From Genuine Purity Liposomal NMN

Genuine Purity Liposomal NMN is renowned for its exceptional purity and efficacy in boosting NAD+ levels, crucial for DNA repair…

3 weeks ago
Precision Neuroscience Receives FDA Clearance for High-Resolution Cortical Electrode ArrayPrecision Neuroscience Receives FDA Clearance for High-Resolution Cortical Electrode Array

Precision Neuroscience Receives FDA Clearance for High-Resolution Cortical Electrode Array

Milestone Paves the Way for Commercialization, Unlocks New Research PotentialNEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation…

3 weeks ago
Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

HOUSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company…

3 weeks ago
Notice of General MeetingNotice of General Meeting

Notice of General Meeting

April 17, 2025 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical…

3 weeks ago
gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain InjuriesgammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries

gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Shown to be Effective in Treating Concussive Symptoms Associated with Mild Traumatic Brain Injuries

ROCKAWAY, N.J., April 17, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced…

3 weeks ago
Contrave Weight Loss: Top OTC Contrave Weight Loss Medication Alternative From PhenQContrave Weight Loss: Top OTC Contrave Weight Loss Medication Alternative From PhenQ

Contrave Weight Loss: Top OTC Contrave Weight Loss Medication Alternative From PhenQ

Contrave is taken to help people lose weight. It is a combination of two medicines that work in the brain…

3 weeks ago
Best Berberine Supplement: Top Berberine Supplements For Weight Loss & Blood Sugar From Sugar DefenderBest Berberine Supplement: Top Berberine Supplements For Weight Loss & Blood Sugar From Sugar Defender

Best Berberine Supplement: Top Berberine Supplements For Weight Loss & Blood Sugar From Sugar Defender

Best Berberine Supplement for Weight loss and Blood sugar. It is used for centuries in traditional medicine, berberine is now…

3 weeks ago
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s DiseaseuniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease

~ Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~ ~…

3 weeks ago
NeuroOne® Issues Letter to ShareholdersNeuroOne® Issues Letter to Shareholders

NeuroOne® Issues Letter to Shareholders

Company Now Fully Funded Through at least Fiscal 2026; Company Confirms No Material Impact from Global Tariffs EDEN PRAIRIE, Minn.,…

3 weeks ago